Lourd Capital LLC maintained its stake in shares of Idexx Laboratories Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,229 shares of the company’s stock at the end of the second quarter. Lourd Capital LLC’s holdings in Idexx Laboratories were worth $300,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in IDXX. Geode Capital Management LLC increased its stake in shares of Idexx Laboratories by 4.0% in the first quarter. Geode Capital Management LLC now owns 576,331 shares of the company’s stock worth $45,138,000 after buying an additional 22,351 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Idexx Laboratories by 43.2% in the first quarter. Goldman Sachs Group Inc. now owns 391,756 shares of the company’s stock worth $30,683,000 after buying an additional 118,115 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Idexx Laboratories by 242.6% in the first quarter. Renaissance Technologies LLC now owns 437,504 shares of the company’s stock worth $34,265,000 after buying an additional 309,804 shares in the last quarter. Smith Asset Management Group LP purchased a new stake in shares of Idexx Laboratories during the second quarter worth approximately $12,467,000. Finally, Seaward Management Limited Partnership increased its stake in shares of Idexx Laboratories by 1.1% in the second quarter. Seaward Management Limited Partnership now owns 18,230 shares of the company’s stock worth $1,692,000 after buying an additional 200 shares in the last quarter. Institutional investors own 91.51% of the company’s stock.
Idexx Laboratories Inc. (NASDAQ:IDXX) traded up 0.173% during midday trading on Wednesday, reaching $112.765. The company had a trading volume of 202,789 shares. Idexx Laboratories Inc. has a 12 month low of $63.48 and a 12 month high of $117.84. The firm has a 50-day moving average of $112.27 and a 200-day moving average of $97.24. The stock has a market cap of $10.10 billion, a P/E ratio of 51.117 and a beta of 0.41.
Idexx Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 2nd. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.62 by $0.12. Idexx Laboratories had a negative return on equity of 414.67% and a net margin of 11.94%. The company had revenue of $467 million for the quarter, compared to the consensus estimate of $444.83 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities analysts expect that Idexx Laboratories Inc. will post $2.36 EPS for the current fiscal year.
Several research firms recently commented on IDXX. Canaccord Genuity restated a “buy” rating and set a $120.00 target price on shares of Idexx Laboratories in a research report on Monday, August 22nd. Bank of America Corp. restated a “neutral” rating on shares of Idexx Laboratories in a research report on Thursday, September 29th. Stifel Nicolaus raised their target price on Idexx Laboratories from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. Zacks Investment Research downgraded Idexx Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Finally, Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Idexx Laboratories presently has a consensus rating of “Buy” and an average price target of $106.20.
In other news, Director Barry C. Johnson sold 9,924 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $111.37, for a total value of $1,105,235.88. Following the transaction, the director now owns 13,484 shares of the company’s stock, valued at $1,501,713.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Jonathan W. Ayers sold 60,000 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $107.69, for a total value of $6,461,400.00. The disclosure for this sale can be found here. 2.79% of the stock is owned by insiders.
About Idexx Laboratories
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories Inc. (NASDAQ:IDXX).
Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.